Ubs Group Ag Nurix Therapeutics, Inc. Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 75,113 shares of NRIX stock, worth $942,668. This represents 0.0% of its overall portfolio holdings.

Number of Shares

75,113

Previous 102,866 26.98%

Holding current value

$942,668

Previous $2.31 Million 38.72%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$18.64 - $28.14 $517,315 - $780,969	-27,753 Reduced 26.98%	75,113 $1.42 Million
Q3 2024 Nov 14, 2024	SELL	$18.93 - $25.69 $297,144 - $403,255	-15,697 Reduced 13.24%	102,866 $2.31 Million
Q2 2024 Aug 13, 2024	SELL	$12.02 - $21.3 $605,555 - $1.07 Million	-50,379 Reduced 29.82%	118,563 $2.47 Million
Q1 2024 May 13, 2024	BUY	$7.77 - $15.66 $719,035 - $1.45 Million	92,540 Added 121.12%	168,942 $2.48 Million
Q4 2023 Feb 09, 2024	SELL	$4.25 - $10.71 $406,300 - $1.02 Million	-95,600 Reduced 55.58%	76,402 $788,000
Q3 2023 Nov 09, 2023	BUY	$7.86 - $10.08 $718,050 - $920,858	91,355 Added 113.28%	172,002 $1.35 Million
Q2 2023 Aug 11, 2023	SELL	$8.7 - $13.28 $38,810 - $59,242	-4,461 Reduced 5.24%	80,647 $805,000
Q1 2023 May 12, 2023	SELL	$8.56 - $13.26 $506,700 - $784,912	-59,194 Reduced 41.02%	85,108 $755,000
Q4 2022 Feb 08, 2023	BUY	$9.86 - $14.59 $1.01 Million - $1.5 Million	102,511 Added 245.29%	144,302 $1.58 Million
Q3 2022 Nov 10, 2022	SELL	$12.33 - $19.81 $216,391 - $347,665	-17,550 Reduced 29.57%	41,791 $545,000
Q2 2022 Aug 10, 2022	SELL	$7.88 - $14.82 $704,180 - $1.32 Million	-89,363 Reduced 60.09%	59,341 $752,000
Q1 2022 May 16, 2022	BUY	$12.94 - $29.65 $638,808 - $1.46 Million	49,367 Added 49.7%	148,704 $2.08 Million
Q4 2021 Feb 14, 2022	BUY	$26.43 - $34.5 $2.61 Million - $3.41 Million	98,762 Added 17176.0%	99,337 $2.88 Million
Q3 2021 Nov 15, 2021	SELL	$22.71 - $36.69 $430,536 - $695,569	-18,958 Reduced 97.06%	575 $17,000
Q2 2021 Aug 13, 2021	SELL	$24.21 - $35.89 $312,526 - $463,304	-12,909 Reduced 39.79%	19,533 $518,000
Q1 2021 May 12, 2021	BUY	$26.98 - $50.17 $875,285 - $1.63 Million	32,442 New	32,442 $1.01 Million

Others Institutions Holding NRIX

# of Institutions

184

Shares Held

67M

Call Options Held

318K

Put Options Held

42.4K

View Full List

About Nurix Therapeutics, Inc.

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $592M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

More about NRIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account